Retinoblastoma-on-a-chip and Therapeutic Strategies
Retinoblastoma (RB) is the most common intraocular tumor of childhood. To date, in vitro studies of retinoblastoma have involved static cell culture systems with limited relevance to in vivo tumors.
In this webinar, we will present the development of a first of its kind RB-on-a-chip system based on MIVO millifluidic technology, designed to support dynamic culture conditions and advanced drug-testing applications. The system enables the investigation of RB cell behavior and treatment response within a controlled microenvironment that more closely mimics in vivo tumor physiology.
This new platform will allow for high‐throughput testing of new drugs and therapeutics with decreased cost, ethical advantages over animal studies and reproducible conditions that more closely approximate the circulating in vivo tumor environment.
INFO
About the speakers
ABOUT THE SPEAKERS
Dr. Gail M. Seigel, Ph.D, FARVO is a Research Professor at the University at Buffalo and a Fellow of the Association for Research in Vision and Ophthalmology. She has been active in the retinoblastoma field for over 30 years, with studies that include retinoblastoma tumor cell growth, differentiation, stem cell marker expression, and targeted therapies. Dr. Seigel has been a recipient of a Fight for Sight Grant-in-Aid with an Award of Merit, Alumni Achievement Award and Scientist Research Partners Award. Dr. Seigel’s current research involves developing new targets and treatments for retinoblastoma, a childhood eye tumor.
Explore past sessions, expert insights, and access recorded sessions
Past Webinars
Explore past sessions, expert insights, and access recorded sessions
